Q&A on RSV Maternal Vaccine and Antibody Candidates to Protect Infants
Nearly all children get sick from respiratory syncytial virus, or RSV, by the age of 2, and last year, there was a notable surge in RSV-associated hospitalizations. But the Food and Drug Administration is now considering approval of a vaccine and a monoclonal antibody aimed at protecting infants from this common virus. We’ll explain what we know so far about these medical products and the risks of RSV for young children.
RSV circulates in colder weather and causes a mild cold in most people. But infants and older adults can experience serious and dangerous illness. As we explained in a companion story, several potential vaccines for older adults are in the works, including one from Pfizer and another from GSK that could get a decision from the FDA in a few months.
Pfizer’s vaccine also has been administered to pregnant people in a clinical trial to determine whether the antibodies they develop in response to vaccination can then protect their babies up to 6 months of age. The company has applied for FDA approval for that use as well. Meanwhile, Sanofi and AstraZeneca have asked the FDA to approve a monoclonal antibody injection for newborns and infants, which, while not a vaccine, would act like one in preventively protecting babies from RSV illness.
As we’ve reported, children’s hospitals across the country were at full capacity last fall due to a spike in RSV infections. But scientists have been working on ways to prevent the illness for decades, and the current crop of candidates is due to scientific advances in 2013.
We don’t know if the products — both those for older adults and those for infants — will be approved by the FDA. But if they are, they could be available for the next RSV season this fall.
What is RSV illness in children,
You’re reading a preview, subscribe to read more.
Start your free 30 days